Opdivo/Yervoy continues to impress in kidney cancer
admin 21st February 2020 Uncategorised 0The results represent the longest follow-up with any immuno-oncology–based therapy in previously untreated RCC patients. More: Opdivo/Yervoy continues to impress in kidney cancer Source: News
read more